Identifying Potential Diagnostic Genes for Diabetic Nephropathy Based on Hypoxia and Immune Status

References

• Koay Y, Tan G, Phang S, et al. A phase IIb randomized controlled trial investigating the effects of tocotrienol-rich vitamin E on diabetic kidney disease. Nutrients. 2021;13(1):258. doi:10.3390/nu13010258
   PubMed Web of Science ®Google Scholar
• Wende AR, Schell JC, Ha C-M, et al. Maintaining myocardial glucose utilization in diabetic cardiomyopathy accelerates mitochondrial dysfunction. Diabetes. 2020;69(10):2094–2111. doi:10.2337/db19-1057
   PubMed Web of Science ®Google Scholar
• Lord T, Nixon B. Metabolic changes accompanying spermatogonial stem cell differentiation. Dev Cell. 2020;52(4):399–411. doi:10.1016/j.devcel.2020.01.014
   PubMed Web of Science ®Google Scholar
• Srivastava A, Tomar B, Prajapati S, Gaikwad AB, Mulay SR. Advanced non-invasive diagnostic techniques for visualization and estimation of kidney fibrosis. Drug Discov Today. 2021;26(8):2053–2063. doi:10.1016/j.drudis.2021.02.016
   PubMed Web of Science ®Google Scholar
• de Bhailís ÁM, Chrysochou C, Kalra PA. Inflammation and oxidative damage in ischaemic renal disease. Antioxidants. 2021;10(6):845. doi:10.3390/antiox10060845
   Web of Science ®Google Scholar
• Spencer S, Wheeler-Jones C, Elliott J. Hypoxia and chronic kidney disease: possible mechanisms, therapeutic targets, and relevance to cats. Vet J. 2021;274:105714. doi:10.1016/j.tvjl.2021.105714
   PubMed Web of Science ®Google Scholar
• Scholz H, Boivin FJ, Schmidt-Ott KM, et al. Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection. Nat Rev Nephrol. 2021;17(5):335–349. doi:10.1038/s41581-021-00394-7
   PubMed Web of Science ®Google Scholar
• Tang SC, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol. 2020;16(4):206–222. doi:10.1038/s41581-019-0234-4
   PubMed Web of Science ®Google Scholar
• Lee H, Fessler MB, Qu P, Heymann J, Kopp JB. Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney disease. BMC Nephrol. 2020;21(1):1–13. doi:10.1186/s12882-020-01921-7
   Web of Science ®Google Scholar
• Herrmann SM, Perazella MA. Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep. 2020;5(8):1139–1148. doi:10.1016/j.ekir.2020.04.018
   PubMed Web of Science ®Google Scholar
• Tong X, Yu Q, Ankawi G, Pang B, Yang B, Yang H. Insights into the role of renal biopsy in patients with T2DM: a literature review of global renal biopsy results. Diabetes Ther. 2020;1–17. doi:10.1007/s13300-020-00888-w
   Web of Science ®Google Scholar
• Sun L, Shang J, Xiao J, Zhao Z. Development and validation of a predictive model for end-stage renal disease risk in patients with diabetic nephropathy confirmed by renal biopsy. PeerJ. 2020;8:e8499. doi:10.7717/peerj.8499
   PubMed Web of Science ®Google Scholar
• Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22:3–15. doi:10.1111/dom.14007
   PubMed Web of Science ®Google Scholar
• Kim HR, Na KR, Lee JI, et al. Progression to chronic kidney disease according to albuminuria in diabetic nephropathy patients with preserved renal function. 2020.
   Google Scholar
• Ihara K, Skupien J, Kobayashi H, et al. Erratum. profibrotic circulating proteins and risk of early progressive renal decline in patients with type 2 diabetes with and without albuminuria. Diabetes Care. 2021;44(2):631. doi:10.2337/dc20-0630
   PubMed Web of Science ®Google Scholar
• Li L, Jick S, Breitenstein S, Michel A. Prevalence of diabetes and diabetic nephropathy in a large US commercially insured pediatric population, 2002–2013. Diabetes Care. 2016;39(2):278–284. doi:10.2337/dc15-1710
   PubMed Web of Science ®Google Scholar
• Woroniecka KI, Park ASD, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes. 2011;60(9):2354–2369. doi:10.2337/db10-1181
   PubMed Web of Science ®Google Scholar
• Pan Y, Jiang S, Hou Q, et al. Dissection of glomerular transcriptional profile in patients with diabetic nephropathy: SRGAP2a protects podocyte structure and function. Diabetes. 2018;67(4):717–730. doi:10.2337/db17-0755
   PubMed Web of Science ®Google Scholar
• Fan Y, Yi Z, D’Agati VD, et al. Comparison of kidney transcriptomic profiles of early and advanced diabetic nephropathy reveals potential new mechanisms for disease progression. Diabetes. 2019;68(12):2301–2314. doi:10.2337/db19-0204
   PubMed Web of Science ®Google Scholar
• Trendafilov N, Gallo M. Principal Component Analysis (PCA). Multivariate Data Analysis on Matrix Manifolds. Springer; 2021:89–139. doi:10.1007/978-1-4419-9863-7_1276
   Google Scholar
• Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm. 2012;2012:146154. doi:10.1155/2012/146154
   PubMed Web of Science ®Google Scholar
• Blank M, Thompson A, Hausner E, Rouse R. Biomarkers of drug-induced acute kidney injury: a regulatory perspective. Expert Opin Drug Metab Toxicol. 2018;14(9):929–936. doi:10.1080/17425255.2018.1511701
   PubMed Web of Science ®Google Scholar
• Chawla L, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13(4):241–257. doi:10.1038/nrneph.2017.2
   PubMed Web of Science ®Google Scholar
• Thomas M, Blaine C, Dawnay A, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87(1):62–73. doi:10.1038/ki.2014.328
   PubMed Web of Science ®Google Scholar
• Askenasy N. Mechanisms of autoimmunity in the non-obese diabetic mouse: effector/regulatory cell equilibrium during peak inflammation. Immunology. 2016;147(4):377–388. doi:10.1111/imm.12581
   PubMed Web of Science ®Google Scholar
• Zheng Z, Zheng F. Immune cells and inflammation in diabetic nephropathy. J Diabetes Res. 2016;2016:1841690. doi:10.1155/2016/1841690
   PubMed Web of Science ®Google Scholar
• Ma W, Gao F, Gu K, Chen D. The role of monocytes and macrophages in autoimmune diseases: a comprehensive review. Front Immunol. 2019;10:1140. doi:10.3389/fimmu.2019.01140
   PubMed Web of Science ®Google Scholar
• Bayati F, Mohammadi M, Valadi M, Jamshidi S, Foma A, Sharif-Paghaleh E. The therapeutic potential of regulatory T cells: challenges and opportunities. Front Immunol. 2020;11:585819. doi:10.3389/fimmu.2020.585819
   PubMed Web of Science ®Google Scholar
• Li S, Jia Y, Xue M, et al. Inhibiting Rab27a in renal tubular epithelial cells attenuates the inflammation of diabetic kidney disease through the miR-26a-5p/CHAC1/NF-kB pathway. Life Sci. 2020;261:118347. doi:10.1016/j.lfs.2020.118347
   PubMed Web of Science ®Google Scholar
• Salti T, Khazim K, Haddad R, Campisi-Pinto S, Bar-Sela G, Cohen I. Glucose induces IL-1α-dependent inflammation and extracellular matrix proteins expression and deposition in renal tubular epithelial cells in diabetic kidney disease. Front Immunol. 2020;11:1270. doi:10.3389/fimmu.2020.01270
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ma X, Han J, et al. Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB/miR-155-5p inflammatory loop. World J Diabetes. 2021;12(1):19–46. doi:10.4239/wjd.v12.i1.19
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang Y, Ren J. Acetylation in cardiovascular diseases: molecular mechanisms and clinical implications. Biochimica Et Biophysica Acta Mol Basis Dis. 2020;1866(10):165836. doi:10.1016/j.bbadis.2020.165836
   PubMed Web of Science ®Google Scholar
• Zouhal H, Zare-Kookandeh N, Haghighi M, et al. Physical activity and adipokine levels in individuals with type 2 diabetes: a literature review and practical applications. Rev Endocr Metab Disord. 2021. doi:10.1007/s11154-021-09657-x
   PubMed Web of Science ®Google Scholar
• Hu C, Klopfer E, Ray P. Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease. FEBS Lett. 2012;586(7):947–955. doi:10.1016/j.febslet.2012.03.002
   PubMed Web of Science ®Google Scholar
• Neumann C, Silver D, Venkateshwari V, et al. MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma. Mol Metabol. 2020;34:136–145. doi:10.1016/j.molmet.2020.01.011
   PubMed Web of Science ®Google Scholar
• Chen P, Huang Y. CPEB2-eEF2 interaction impedes HIF-1α RNA translation. EMBO J. 2012;31(4):959–971. doi:10.1038/emboj.2011.448
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Gjølberg T, Krüger S, Haraldsen G, Andersen J, Sundlisæter E. Targeting the notch signaling pathway in chronic inflammatory diseases. Front Immunol. 2021;12:668207. doi:10.3389/fimmu.2021.668207
   PubMed Web of Science ®Google Scholar
• Mills C, Kincaid K, Alt J, Heilman M, Hill A. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164(12):6166–6173. doi:10.4049/jimmunol.164.12.6166
   PubMed Web of Science ®Google Scholar
• De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44(1):19. doi:10.3858/emm.2012.44.1.025
   Web of Science ®Google Scholar
• Carney E. Proteasome impairment can lead to CKD. Nat Rev Nephrol. 2021;17(4):222. doi:10.1038/s41581-021-00409-3
   Web of Science ®Google Scholar
• Jones M, Zha J, Humphries M. Connections between the cell cycle, cell adhesion and the cytoskeleton. Biol Sci. 2019;374(1779):20180227. doi:10.1098/rstb.2018.0227
   Web of Science ®Google Scholar
• Kilian L, Voran J, Frank D, Rangrez A. RhoA: a dubious molecule in cardiac pathophysiology. J Biomed Sci. 2021;28(1):33. doi:10.1186/s12929-021-00730-w
   PubMed Web of Science ®Google Scholar
• Neves K, Harvey A, Moreton F, et al. ER stress and Rho kinase activation underlie the vasculopathy of CADASIL. JCI Insight. 2019;4(23). doi:10.1172/jci.insight.131344
   PubMed Web of Science ®Google Scholar
• Wang E, Tu W, Do D, et al. Benzo(a)pyrene enhanced dermatophagoides group 1 (Der f 1)-induced TGFβ1 signaling activation through the aryl hydrocarbon receptor-rhoa axis in asthma. Front Immunol. 2021;12:643260. doi:10.3389/fimmu.2021.643260
   PubMed Web of Science ®Google Scholar
• Komers R. Rho kinase inhibition in diabetic kidney disease. Br J Clin Pharmacol. 2013;76(4):551–559. doi:10.1111/bcp.12196
   PubMed Web of Science ®Google Scholar
• Matoba K, Kawanami D, Okada R, et al. Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α. Kidney Int. 2013;84(3):545–554. doi:10.1038/ki.2013.130
   PubMed Web of Science ®Google Scholar
• Sinha S, Dwivedi N, Woodgett J, et al. Glycogen synthase kinase-3β inhibits tubular regeneration in acute kidney injury by a FoxM1-dependent mechanism. FASEB J. 2020;34(10):13597–13608. doi:10.1096/fj.202000526RR
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang W, Su S, et al. Roles of 12-lipoxygenase and its interaction with angiotensin II on p21 and p27 expression in diabetic nephropathy. Nephron. 2019;142(1):61–70. doi:10.1159/000496440
   PubMed Web of Science ®Google Scholar
• Merscher-Gomez S, Guzman J, Pedigo CE, et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes. 2013;62(11):3817–3827. doi:10.2337/db13-0399
   PubMed Web of Science ®Google Scholar
• Iwata Y, Furuichi K, Hashimoto S, et al. Pro-inflammatory/Th1 gene expression shift in high glucose stimulated mesangial cells and tubular epithelial cells. Biochem Biophys Res Commun. 2014;443(3):969–974. doi:10.1016/j.bbrc.2013.12.072
   PubMed Web of Science ®Google Scholar
• Shved N, Warsow G, Eichinger F, et al. Transcriptome-based network analysis reveals renal cell type-specific dysregulation of hypoxia-associated transcripts. Sci Rep. 2017;7(1):8576. doi:10.1038/s41598-017-08492-y
   PubMedGoogle Scholar